Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America

Our objective was to describe the risk of hospital admission for virologically confirmed dengue (VCD) and the risk of clinically severe hospitalized VCD occurring up to 4 years after the first dose (years 1 to 4) in three randomized clinical trials comparing tetravalent dengue vaccine with placebo....

Full description

Saved in:

Bibliographic Details
Published in:	Clinical microbiology and infection Vol. 24; no. 7; pp. 755 - 763
Main Authors:	Arredondo-García, J.L., Hadinegoro, S.R., Reynales, H., Chua, M.N., Rivera Medina, D.M., Chotpitayasunondh, T., Tran, N.H., Deseda, C.C., Wirawan, D.N., Cortés Supelano, M., Frago, C., Langevin, E., Coronel, D., Laot, T., Perroud, A.P., Sanchez, L., Bonaparte, M., Limkittikul, K., Chansinghakul, D., Gailhardou, S., Noriega, F., Wartel, T.A., Bouckenooghe, A., Zambrano, B.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-07-2018
Subjects:	Children Dengue disease Dengue vaccine Long-term follow up Vaccine safety Long-term follow up Vaccine safety Children Dengue disease Dengue vaccine Long-term follow-up
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Our objective was to describe the risk of hospital admission for virologically confirmed dengue (VCD) and the risk of clinically severe hospitalized VCD occurring up to 4 years after the first dose (years 1 to 4) in three randomized clinical trials comparing tetravalent dengue vaccine with placebo. The relative risks (RR) for hospitalized VCD from first dose to year 4 were estimated by year and age-group in individual and combined studies. Overall, from Year 1 to Year 4, 233 and 228 participants had at least one episode of hospitalized VCD in the vaccinated (n = 22 603) and placebo (n = 11 301) groups, respectively (RR = 0.511, 95% CI 0.42–0.62). Among these, 48 and 47 cases, respectively, were classified as clinically severe. In children aged ≥9 years, 88 and 136 participants had at least one episode of hospitalized VCD in the vaccinated (n = 17 629) and placebo (n = 8821) groups, respectively (RR = 0.324; 95% CI 0.24–0.43). In vaccinated participants aged <9 years, particularly in those aged 2–5 years, there were more hospitalized VCD cases compared with the control participants in Year 3 but not in Year 4. The overall RR in those aged <9 years for Year 1 to Year 4 was 0.786 (95% CI 0.60–1.03), with a higher protective effect in the 6–8 year olds than in the 2–5 year olds. The overall benefit-risk remained positive in those aged ≥9 years up to year 4, although the protective effect was lower in years 3 and 4 than in years 1 and 2.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1198-743X 1469-0691
DOI:	10.1016/j.cmi.2018.01.018